Neon Therapeutics, Inc. reported financial results for the third quarter of 2018. For the quarter, the company reported net loss attributable to common stockholders of $18.391 million $0.67 per basic and diluted share as compared to a net loss attributable to common stockholders of $16.519 million or $9.59 per basic and diluted share a year ago. Loss from operations were $19.053 million compared to loss from operations of $14.142 million same period last year. For the nine months, net loss attributable to common stockholders was $60.182 million or $5.55 per basic and diluted share as compared to a net loss attributable to common stockholders of $40.569 million for the same period last year or $25.33 per basic and diluted share. Loss from operations were $54.927 million compared to loss from operations of $33.454 million same period last year.